Don’t Miss: Merrimack Pharmaceuticals (NASDAQ:MACK), Acorda Therapeutics (NASDAQ:ACOR), USA Compression Partners, LP (NYSE:USAC), Halliburton Company (NYSE:HAL), Google Inc. (NASDAQ:GOOG)

On 4 AUG Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that the company will host its Second Quarter 2014 Investor Conference Call on Monday, August 11. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) belongs to Healthcare sector. Its weekly performance is 12.98%. On last trading day company shares ended up $6.53. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is -5.40%. On 31 JULY Acorda Therapeutics, Inc. … Continue reading Don’t Miss: Merrimack Pharmaceuticals (NASDAQ:MACK), Acorda Therapeutics (NASDAQ:ACOR), USA Compression Partners, LP (NYSE:USAC), Halliburton Company (NYSE:HAL), Google Inc. (NASDAQ:GOOG)

Kevin Long08/1108/11

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz06/2606/26

Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately … Continue reading Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)

Kristen Barton06/2606/26

Gilead Sciences GILD NASDAQ:GILD

Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

InterMune, Inc. (NASDAQ:ITMN) on 27 May 2014 announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in May 2010. Pirfenidone is being developed for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF). InterMune Inc (NASDAQ:ITMN) stock performance was -0.88% in last session and finished … Continue reading Hot Biotech Watch List: InterMune Inc (NASDAQ:ITMN), Merrimack Pharmaceuticals (NASDAQ:MACK), China Biologic Products (NASDAQ:CBPO), VIVUS (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA)

Kristen Barton05/2805/28

Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both … Continue reading Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Kevin Long05/2805/28

Volatile Stocks: MeetMe Inc (NASDAQ:MEET), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Dillard’s (NYSE:DDS), Just Energy Group (NYSE:JE)

MeetMe Inc (NASDAQ:MEET), the public market leader for social discovery, has released Icebreakers, a new feature for the MeetMe iPhone app that makes it easier for users to start a chat. “Icebreakers solves the problem of the empty chat screen,” said Geoff Cook, CEO of MeetMe. “Rather than starting conversations with a generic ‘Hi’ or ‘What’s up,’ or possibly not starting them at all for … Continue reading Volatile Stocks: MeetMe Inc (NASDAQ:MEET), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Dillard’s (NYSE:DDS), Just Energy Group (NYSE:JE)

Kristen Barton05/1905/19